These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 32656953)

  • 1. Pityriasis lichenoides triggered by measles-mumps-rubella vaccine injection.
    Filippi F; Patrizi A; Sabattini E; Varotti E; Bertuzzi C; Pileri A
    J Dtsch Dermatol Ges; 2020 Jul; 18(7):758-760. PubMed ID: 32656953
    [No Abstract]   [Full Text] [Related]  

  • 2. Pityriasis lichenoides chronic after measles-mumps-rubella vaccination.
    Gil-Bistes D; Kluger N; Bessis D; Guillot B; Raison-Peyron N
    J Dermatol; 2012 May; 39(5):492-3. PubMed ID: 21967266
    [No Abstract]   [Full Text] [Related]  

  • 3. Pityriasis lichenoides et varioliformis acuta: a rare association with the measles, mumps and rubella vaccine.
    Gunatheesan S; Ferguson J; Moosa Y
    Australas J Dermatol; 2012 Nov; 53(4):e76-8. PubMed ID: 23157791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pityriasis lichenoides et varioliformis acuta after influenza vaccine.
    Castro BA; Pereira JM; Meyer RL; Trindade FM; Pedrosa MS; Piancastelli AC
    An Bras Dermatol; 2015; 90(3 Suppl 1):181-4. PubMed ID: 26312710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pityriasis lichenoides et varioliformis acuta following measles rubella vaccine.
    Shastry V; Ranugha PSS; Rangappa V; Sanjaykumar P
    Indian J Dermatol Venereol Leprol; 2020; 86(4):398-400. PubMed ID: 32474500
    [No Abstract]   [Full Text] [Related]  

  • 6. Pityriasis lichenoides et varioliformis acuta following anti-tetanus and diphtheria adult vaccine.
    Merlotto MR; Bicudo NP; Marques MEA; Marques SA
    An Bras Dermatol; 2020; 95(2):259-260. PubMed ID: 32156502
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study.
    Abu-Elyazeed R; Jennings W; Severance R; Noss M; Caplanusi A; Povey M; Henry O
    Hum Vaccin Immunother; 2018; 14(11):2624-2631. PubMed ID: 29902133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
    Nolan T; McIntyre P; Roberton D; Descamps D
    Vaccine; 2002 Dec; 21(3-4):281-9. PubMed ID: 12450703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.
    Feiterna-Sperling C; Brönnimann R; Tischer A; Stettler P; Durrer P; Gaedicke G
    Pediatr Infect Dis J; 2005 Dec; 24(12):1083-8. PubMed ID: 16371870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
    Leung JH; Hirai HW; Tsoi KK
    Expert Rev Vaccines; 2015; 14(8):1149-57. PubMed ID: 26081133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps rubella, and varicella vaccine (MMRV) manufactured using an alternative process.
    Marshall GS; Senders SD; Shepard J; Twiggs JD; Gardner J; Hille D; Hartzel J; Valenzuela R; Stek JE; Helmond FA
    Hum Vaccin Immunother; 2016 Aug; 12(8):2188-2196. PubMed ID: 27149048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
    Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
    Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial.
    Sood A; Mitra M; Joshi HA; Nayak US; Siddaiah P; Babu TR; Mahapatro S; Sanmukhani J; Gupta G; Mittal R; Glueck R
    Hum Vaccin Immunother; 2017 Jul; 13(7):1523-1530. PubMed ID: 28362563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measles, mumps, and rubella virus vaccine (M-M-R™II): a review of 32 years of clinical and postmarketing experience.
    Lievano F; Galea SA; Thornton M; Wiedmann RT; Manoff SB; Tran TN; Amin MA; Seminack MM; Vagie KA; Dana A; Plotkin SA
    Vaccine; 2012 Nov; 30(48):6918-26. PubMed ID: 22959986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines.
    Schwarzer S; Reibel S; Lang AB; Struck MM; Finkel B; Gerike E; Tischer A; Gassner M; Glück R; Stück B; Cryz SJ
    Vaccine; 1998; 16(2-3):298-304. PubMed ID: 9607046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella.
    Nascimento Silva JR; Camacho LA; Siqueira MM; Freire Mde S; Castro YP; Maia Mde L; Yamamura AM; Martins RM; Leal Mde L;
    Vaccine; 2011 Aug; 29(37):6327-34. PubMed ID: 21640779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial.
    MMR-161 Study Group
    Vaccine; 2018 Sep; 36(38):5781-5788. PubMed ID: 30104117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children.
    Lee CY; Tang RB; Huang FY; Tang H; Huang LM; Bock HL
    Int J Infect Dis; 2002 Sep; 6(3):202-9. PubMed ID: 12718836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
    MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
    Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.